Oncotelic has two pharmacological agents in clinical trials to manage Covid-19, the disease caused by the SARS-CoV-2 virus. OT-101 and ARTIVeda both work by inhibiting TGF-β to neutralize the SARS-CoV-2 virus.
Upon assessing the broad impact of the SARS-CoV-2 virus and associated COVID-19 complications, the company tested OT-101 and Artemisinin, both of which showed potent activity in the lab and promising data for treating the virus infection and associated complications based on the their mechanism of action.
| Study Title | Intervention | Control | Status |
|---|---|---|---|
| A Double-Blind, Randomized, Placebo Controlled, Multi-Center Study of OT 101 in Hospitalized COVID-19 Subjects: C001 2020 01 | OT-101 | Standard of Care | Recruiting |
| A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19: ARTI/WBPL/P4/2020/01 | ArtiVeda | Standard of Care | Recruiting |
| A Double Blind, Randomized, Placebo Controlled, Multi Center Study of OT 101 in Hospitalized COVID 19 Subjects: C002-2020-01 | OT-101+ARTIVeda | Standard of Care+ARTIVeda | Not yet recruiting |
| A Prospective, Randomized, Multi-center, Open label, Interventional Study to Evaluate the Safety and Efficacy of Artemisinin 500 mg capsule in Treatment of Adult Subjects with COVID-19: ARTI/OT/P2/2020/01 | ARTIVeda | Standard of Care | Not yet recruiting |
ARTIVeda
TGF-β inhibitor to address the COVID-19 pandemic in India. A similar product, ArtiShield, will be available outside of India.
OT-101
OT-101 has a similar mechanism of action as ARTIVeda, and is currently in phase 2 testing.